Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 07 May 2026 | Chiara Galiffa Cabinet member | Latest developments in EU-US relations | SRC |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 21 Sept 2023 | Patricia Reilly Cabinet member | Discussions covered AbbVie’s presence in Europe including 5 major sites in Ireland; the sector’s demand for skills and training; the pharmaceutical strategy for Europe and access to medicine in Ireland. | — |
| 21 Sept 2023 | Patricia Reilly Cabinet member | Discussions covered AbbVie’s presence in Europe including 5 major sites in Ireland; the sector’s demand for skills and training; the pharmaceutical strategy for Europe and access to medicine in Ireland. | SRC |
| 05 Jun 2023 | Zaneta Vegnere Cabinet member | Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement | — |
| 05 Jun 2023 | Zaneta Vegnere Cabinet member | Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement | SRC |
| 24 Nov 2020 | Alina-Stefania Ujupan Cabinet member | Pharmaceutical innovation and research in Europe | — |
| 24 Nov 2020 | Alina-Stefania Ujupan Cabinet member | Pharmaceutical innovation and research in Europe | SRC |
| 24 May 2018 | Tom Tynan Cabinet member | Business discussion | SRC |
| 24 May 2018 | Tom Tynan Cabinet member | Business discussion | — |
| 27 Mar 2018 | Leila Fernandez-Stembridge Cabinet member | IP regime generic manufacturers in the pharmaceutical industry | — |
| 27 Mar 2018 | Leila Fernandez-Stembridge Cabinet member | IP regime generic manufacturers in the pharmaceutical industry | SRC |
| 26 Mar 2018 | Nele Eichhorn Cabinet member | SPC waiver | SRC |
| 26 Mar 2018 | Nele Eichhorn Cabinet member | SPC waiver | — |
Mission & Goals
AbbVie is a Specialty-focused, research-based biopharmaceutical company focused on developing new products and new ways to help people manage some of the most serious health conditions. We are scientists, researchers, communicators, manufacturing specialists, and regulatory experts. AbbVie began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott. Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries. On January 1, 2013, AbbVie was founded, a global biopharmaceutical company with the focus and capabilities to address some of the world's greatest health challenges. AbbVie has the stability, resources, expertise, and passion to discover, develop, and bring to market groundbreaking science to solve the biggest health problems that face the world today (...)
EU Legislative Interests
- Pharmaceutical Strategy, and in particular review of the basic pharmaceutical legislation - European Health Data Space - Industrial Policies, and in particular questions around patents, SPC and so on. - Competition in the pharmaceutical sector - Revision of Medical Device and IVD Regulation - Urban Wastewater Directive - PFAS - Packaging and Packaging Waste Directive - European Commission activities around ensuring effective, resilient and sustainable healthcare systems - Access to Medicines - Beating cancer plan - Omnibus Legislation - EU HTA Regulation - Clinical Trials Regulation - Critical Medicines Act - EU Life Sciences Strategy - EU Biotech Act - Women's health - Brain health related initiatives
Communication Activities
AbbVie has supported a number of roundtables that were hosted by members of the European Parliament, speaking engagements at third party conferences, and has also participated in the EU public debate through op-eds that were published in the relevant trade press.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
- American Chamber of Commerce to the EU - European Federation of Pharmaceutical Industries and Association (EFPIA)
Organisation Members
- European Cancer Organization - European Brain Council
Additional Information
Since 2022 and the new interinstitutonal agreement and the guidelines issued in that context, the reporting structure has changed. This led to adding additional employees and their salaries whose activities are now considered in-scope, as well as to counting the membership fees to organization we are members of (which we previously excluded to avoid double reporting).
Connected Legislation